Latest stories on VERA
Raymond James reiterates Vera Therapeutics stock Strong Buy on kidney disease data
Investing.com Analyst Ratings64 · neutralanalyst
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on kidney drug data
Investing.com Analyst Ratings52 · neutralanalyst
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Seeking Alpha58 · neutralearnings
Vera Therapeutics announces publication of ORIGIN 3 final efficacy analysis
The Fly63 · neutralproduct/pr
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Business Insider56 · neutralproduct/pr
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
GlobeNewswire56 · neutralproduct/pr
Vera Therapeutics initiated with a Market Perform at Leerink
The Fly52 · neutralanalyst
Vera Therapeutics price target lowered to $60 from $66 at BofA
The Fly34 · bearishanalyst
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data
Seeking Alpha56 · neutralproduct/pr
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Barron's73 · bullishproduct/pr
TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data
Investing.com Analyst Ratings61 · neutralanalyst
Vera Therapeutics stock maintained at Strong Buy by Raymond James
Investing.com Analyst Ratings61 · neutralanalyst
Vera Therapeutics ORIGIN 3 study results positive, says Raymond James
The Fly67 · bullishproduct/pr
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints
InvestorsHub73 · bullishproduct/pr
TRUTAKNA Cut ORIGIN 3 Kidney-Progression Risk by 76%; FDA Review Comes Next
TechStock²78 · bullishproduct/pr
VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
Stocktwits News73 · bullishproduct/pr
Morning Movers: Vera Therapeutics surges after reporting IgAN study data
The Fly67 · bullishproduct/pr